William Blair analyst Sami Corwin has reiterated their bullish stance on NGNE stock, giving a Buy rating on May 5.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Sami Corwin has given his Buy rating due to a combination of factors related to Neurogene’s strategic advancements and regulatory prospects. The company’s upcoming regulatory update is expected to clarify the design of the registrational trial for NGN-401, a treatment for Rett syndrome, which is a significant step forward. The discussions with Neurogene’s management highlighted the alignment with the FDA on trial strategies, which include various control strategies that could enhance the trial’s feasibility and effectiveness.
Moreover, the potential use of clinician-evaluated endpoints and the acquisition of skills as co-primary endpoints could involve both clinicians and caregivers in patient assessments, adding robustness to the trial outcomes. The impressive efficacy and durability of response observed in the Phase I trial further strengthen the investment case. These factors collectively suggest a promising outlook for Neurogene, justifying the Buy rating.
According to TipRanks, Corwin is a 3-star analyst with an average return of 1.3% and a 36.05% success rate. Corwin covers the Healthcare sector, focusing on stocks such as PTC Therapeutics, Krystal Biotech, and Allogene Therapeutics.
In another report released on May 5, H.C. Wainwright also maintained a Buy rating on the stock with a $50.00 price target.